Klaus is an accomplished oncology innovator and development leader with extensive experience and expertise in leading oncology drug development, with a proven track record of leading innovative therapies from concept to regulatory approval.

His previous roles include Chief Development Officer (CDO) at Nykode Therapeutics. Before Nykode he was CDO and CMO at Curevac, and Senior Vice President and Head of Global Oncology Development at Merck KgaA, where he was accountable for all aspects of early and late-stage development in oncology. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca and has held senior oncology-focused positions at GSK, Genmab and Aventis (Sanofi).

Klaus holds an M.D. degree as well as a Ph.D. in Cancer Biology from the University of Copenhagen. His academic career includes being a Professor in Experimental Cancer Research at Lund University, Sweden, and a Professor in Cell Biology at the University of Bergen, Norway.